BERY

Analyst Note: Berry Global Group, Inc. (BERY)

Date: 2026-06-13 Current Price: $67.58

1. Structural Readiness

State: Context-Only Conservative Entry: — (Breakout not yet fired) Current Price: $67.58 Extension: — ATR at Breakout: — ATR Current: 3.0% (Productive) Pivot Strength: —

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None Named

At this date (2026-06-13), there is no named secular thesis driving this specific setup. This is a tactical, setup-led name. The conviction must be derived strictly from the quality of the structural setup (the forming coil) and the underlying business fundamentals as recorded by management. No macro themes or industry-wide secular trends are being applied to weight this trade; the judgment rests on the interplay between the technical structure and the company's operational execution.

3. Business Overview

Company: Berry Global Group, Inc. Industry: Packaging Materials / Industrial Materials Business Model: Global producer and distributor of non-woven, flexible, and rigid materials for consumer and industrial applications.

Operational Structure (as of 2026-06-12): The company operates through four key segments, serving over 20,000 customers in 140 countries with 70,000 employees across 400 production facilities:

• Consumer Packaging International: Provides closures, dispensing systems, pharmaceutical devices, bottles, canisters, and technical components.
• Consumer Packaging North America: Offers containers, pails, foodservice products, closures, overcaps, bottles, prescription vials, and tubes.
• Engineered Materials: Produces diverse film products (stretch, shrink, converter, food, consumer, agriculture films), institutional can liners, and retail bags.
• Health, Hygiene & Specialties: Delivers solutions for healthcare, hygiene, and specialty markets, including adhesive tapes.

Strategic Context (Post-Merger Integration): Evidence from the 2024-11-20 earnings transcript indicates the company is in the execution phase of a major strategic combination (referenced as "Amcor" in the source data, likely a merger integration context). Management has outlined a specific synergy realization path:

• Synergy Run Rate: Management expects to reach a full $650 million run rate of synergies in the third year post-close.
• Realization Schedule: 40% of identified synergies realized in Year 1, 40% in Year 2, and the balance in Year 3.
• Cash Flow Target: Annual cash flow (net of interest, tax, and before CapEx) is expected to exceed $3 billion after synergies are fully realized.
• Growth Expectation: The combined business is expected to deliver above-market growth rates, accelerating by at least 100 basis points.
• Portfolio Orientation: Management expects margins to expand as the portfolio orients toward higher-value, higher-growth categories.
• End Markets: More than 90% of sales serve consumer and healthcare end markets.
• Dividend Commitment: Management is committed to growing the annual dividend from Amcor's current annualized base of $0.51 per share.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: The name fits the Quality Compounder archetype based on the structural evidence of a disciplined margin expansion strategy, a clear path to significant cash flow generation ($3B+), and a commitment to shareholder returns (dividend growth). The business model is diversified across four segments with a heavy weighting toward defensive consumer and healthcare end markets (90% of sales), providing stability.

Valuation & Financial Spine: The financial spine indicates a forward consensus EPS of $6.80 for FY1 and $7.20 for FY2. This implies a valuation multiple that is being supported by the expected earnings growth and the realization of the $650M synergy run rate.

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led, no macro thesis).
• Evidence Quality: High (Clear management guidance on synergies, cash flow, and growth acceleration).
• Setup Readiness: Partial (Waiting for breakout confirmation).
• Rerating Potential: Moderate (Dependent on the successful execution of the synergy plan and the technical breakout).

ATR Context: The current ATR of 3.0% is in the "productive" bucket (historical sweet spot is 4–6%, but 3.0% is sufficient for sizing). It is not in the "extreme" (>8%) or "weak" (<2.5%) zones, suggesting the stock is moving with normal volatility suitable for a forming setup.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Fundamental: A deviation from the synergy realization schedule (e.g., missing the 40% Year 1 target) or a failure to maintain the $3B cash flow trajectory.

What Would Strengthen:

• Technical: A confirmed breakout close above the resistance level (breakout level not yet defined in data, but implied as the top of the coil).
• Fundamental: Management raising the synergy guidance or accelerating the realization timeline beyond the 40/40/20 split.

Gaps in Evidence:

• Breakout Level: The specific price level for the breakout (resistance) is not provided in the current data, preventing a precise entry calculation.
• Current Synergy Status: While the *target* is $650M, the *actual* realized synergies as of June 2026 are not explicitly quantified in the provided evidence, only the management expectation.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Technical breakout has not fired (setup incomplete); execution risk on synergy realization timeline; lack of named secular thesis to support multiple expansion. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status; treat as a partial position pending confirmation. Expected path: Price consolidates within the forming range while management executes the synergy plan; a breakout occurs if earnings momentum validates the $3B cash flow target. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation).